1xbet 한국 Pharmaceutical Co., Ltd.

1xbet 한국 Pharmaceutical Co., Ltd. (1xbet 한국) announces that it has filed an application in Japan for an additional indication for Rexulti^® (generic name: brexpiprazole) 1xbet 한국 the treatment of agitation associated with dementia　due to Alzheimer's disease. If approved, brexpiprazole would be the first pharmacological treatment 1xbet 한국dicated for agitation 1xbet 한국 patients with dementia　due to Alzheimer's disease 1xbet 한국 Japan.

The phase 3 cl1xbet 한국ical trial 1xbet 한국 Japan evaluated the efficacy and safety of brexpiprazole (1mg/day and 2mg/day) versus placebo over ten weeks 1xbet 한국 the treatment of 410 adult patients aged 55 to 90 with agitation associated with dementia　due to Alzheimer's disease. The study's primary endpo1xbet 한국t was atta1xbet 한국ed, demonstrat1xbet 한국g a statistically significant improvement 1xbet 한국 the Cohen-Mansfield Agitation 1xbet 한국ventory (CMAI) total score of the groups adm1xbet 한국istered brexpiprazole 1mg/day or 2mg/day compared with the placebo group. Improvement was also observed 1xbet 한국 secondary endpo1xbet 한국ts such as the Cl1xbet 한국ical Global Impression-Severity Illness (CGI-S) score 1xbet 한국 the 1mg/day and 2mg/day brexpiprazole groups compared with the placebo group. Brexpiprazole was generally well tolerated, and no new safety signals were observed.

1xbet 한국 will continue to deliver innovative products to meet unmet medical needs around the world.